XOMA (NASDAQ:XOMA) Raised to “Sell” at ValuEngine

ValuEngine upgraded shares of XOMA (NASDAQ:XOMA) from a strong sell rating to a sell rating in a report published on Wednesday, ValuEngine reports.

Several other equities analysts have also issued reports on XOMA. Wedbush reissued a buy rating and issued a $25.00 price target on shares of XOMA in a report on Wednesday, August 7th. HC Wainwright set a $30.00 price objective on shares of XOMA and gave the company a buy rating in a research report on Friday, September 27th. Finally, Zacks Investment Research raised shares of XOMA from a hold rating to a buy rating and set a $22.00 price objective on the stock in a research report on Saturday, October 26th. One research analyst has rated the stock with a sell rating and three have issued a buy rating to the company’s stock. XOMA currently has a consensus rating of Buy and a consensus price target of $26.33.

Shares of XOMA stock traded up $0.77 during midday trading on Wednesday, reaching $24.00. The company had a trading volume of 130,400 shares, compared to its average volume of 58,340. XOMA has a 1-year low of $11.02 and a 1-year high of $24.12. The company has a market capitalization of $185.02 million, a price-to-earnings ratio of -15.09 and a beta of 1.26. The company has a current ratio of 3.90, a quick ratio of 3.90 and a debt-to-equity ratio of 1.39. The stock has a fifty day simple moving average of $19.09 and a 200 day simple moving average of $17.36.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.48) by $0.68. XOMA had a negative net margin of 10.19% and a negative return on equity of 9.40%. The company had revenue of $8.86 million during the quarter. Sell-side analysts expect that XOMA will post -0.86 earnings per share for the current year.

In related news, CEO James R. Neal sold 5,452 shares of the business’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $20.23, for a total value of $110,293.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Thomas M. Burns sold 3,829 shares of the business’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $21.96, for a total transaction of $84,084.84. Following the completion of the sale, the chief financial officer now directly owns 10,384 shares in the company, valued at $228,032.64. The disclosure for this sale can be found here. Insiders sold a total of 17,459 shares of company stock worth $374,142 over the last ninety days. 9.89% of the stock is currently owned by insiders.

Large investors have recently modified their holdings of the business. Athanor Capital LP bought a new stake in XOMA during the 2nd quarter worth about $149,000. Morgan Stanley lifted its position in XOMA by 2,151.6% during the 2nd quarter. Morgan Stanley now owns 23,889 shares of the biotechnology company’s stock worth $355,000 after buying an additional 22,828 shares in the last quarter. Marshall Wace LLP bought a new stake in XOMA during the 2nd quarter worth about $434,000. Paloma Partners Management Co bought a new stake in XOMA during the 2nd quarter worth about $510,000. Finally, RBF Capital LLC bought a new stake in XOMA during the 2nd quarter worth about $1,479,000. 44.48% of the stock is currently owned by hedge funds and other institutional investors.

About XOMA

XOMA Corporation, a biotech company, discovers and develops therapeutic candidates in the United States, Europe, and the Asia Pacific. The company has a pipeline of monoclonal antibodies and technologies to license to pharmaceutical and biotechnology companies to further their clinical development. Its proprietary product candidates include X213, an allosteric inhibitor of prolactin action; XMetA, an insulin receptor-activating antibody to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients; IL-2, a therapy for metastatic melanoma and renal cell carcinoma; and PTH1R, an anti-parathyroid receptor pipeline to address unmet medical needs, including primary hyperparathyroidism and humoral hypercalcemia of malignancy.

See Also: Green Investing

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for XOMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA and related companies with MarketBeat.com's FREE daily email newsletter.